REG - CVS Group plc - Admission to Trading on the Main Market of the LSE

CVSAnnouncement

29/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260129:nRSc8875Qa&default-theme=true

RNS Number : 8875Q  CVS Group plc  29 January 2026

29 January 2026

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Admission to trading on the Main Market of the London Stock Exchange and AIM
cancellation

 

Further to its announcement on 23 January 2026, CVS is pleased to announce
that the Company's ordinary shares ("Ordinary Shares") will be admitted to the
Equity Shares (Commercial Companies) category of the Official List maintained
by the Financial Conduct Authority ("FCA") and to trading on the Main Market
of the London Stock Exchange (together, "Admission") at 8:00am today and
simultaneously cancelled from trading on AIM.

 

The Company is not offering any new Ordinary Shares nor any other securities
in connection with the proposed Admission. Following Admission, the Ordinary
Shares will continue to be registered with their existing ISIN of GB00B2863827
and the Company's ticker symbol will continue to be CVSG.

 

On Admission, the total number of Ordinary Shares in issue will be 70,156,093.
There are no Ordinary Shares held in Treasury. The aforementioned figure may
be used by shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their interest in,
or a change in their interest in, the share capital of the Company under the
FCA's Disclosure Guidance and Transparency Rules.

 

The Company's shareholders should consult their own professional advisers
regarding the consequences of Admission on their personal tax position.

 

David Wilton, Non-Executive Chair, commented:

 

"Today marks an important milestone for CVS as we join the Main Market of the
London Stock Exchange. The move reflects our confidence in the Group's future
and our commitment to delivering long-term value for all stakeholders. It will
provide access to deeper pools of capital across a broader range of investors,
offer the potential for index inclusion and improvement in trading liquidity,
and enhance our corporate profile, positioning CVS for the next phase of
growth.

 

"I would like to take this opportunity to thank our shareholders for their
continued support, particularly through the challenges faced by the wider
sector in recent years. We are confident in the opportunities ahead and remain
committed to building on this strong foundation and delivering sustainable
growth."

 

"I would also like to take this opportunity to thank CVS colleagues for their
continued dedication and support in providing care to our clients and their
animals"

 

Contacts

CVS Group plc
 
                                               via
Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Berenberg (Sponsor & Joint Broker)
 
                        +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Peel Hunt LLP (Joint Broker)
 
                               +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Camarco (Financial
PR)
                                   cvsg@camarco.co.uk

Ginny Pulbrook
 
                                               +44
(0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is a leading provider of veterinary services with operations in the
UK and Australia.  CVS is focused on providing high-quality clinical services
to its clients and their animals, with outstanding and dedicated clinical and
support teams at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an Online Retail
Business.

 

The Group employs c.8,900 personnel, including c.2,500 veterinary surgeons and
c.3,300 nurses and patient care assistants.

 

Important notices

This announcement contains statements that are, or may be deemed to be,
"forward- looking statements". These forward-looking statements can be
identified by the use of forward‑looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends", "plans", "goal",
"target", "aim", "may", "will", "would", "could" or "should" or, in each case,
their negative or other variations or comparable terminology. All statements
other than statements of historical facts included in this announcement,
including those regarding the Company's strategy, plans and objectives and the
anticipated Admission are forward-looking statements. Readers are cautioned
not to place undue reliance on such statements. Forward-looking statements
involve a number of known and unknown risks, uncertainties and other factors,
many of which are difficult to predict and generally beyond the control of
CVS. These forward-looking statements speak only as of the date of this
announcement. CVS expressly disclaims any obligation or undertaking to update
or revise any forward-looking statement (except to the extent legally
required).

 

Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), which is
authorised and regulated by the German Federal Financial Supervisory Authority
and in the United Kingdom is subject to limited regulation by the FCA, is
acting exclusively for the Company  as Sponsor and no one else in connection
with Admission and it will not regard any other person as a client in relation
to Admission and will not be responsible to anyone other than the Company
for providing the protections afforded to its clients or for providing advice
in relation to Admission or any other transaction, matter, or arrangement
referred to in this announcement.

This announcement has been issued by, and is the sole responsibility of, the
Company. No representation or warranty, express or implied, is or will be made
as to, or in relation to, and no responsibility or liability is or will be
accepted by Berenberg or by any of their affiliates, partners, directors,
officers, employees, advisers or agents as to or in relation to, the accuracy
or completeness of this announcement or any other written or oral information
made available to or publicly available to any interested party or its
advisers, and any liability therefore is expressly disclaimed.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  LISSEASMUEMSELF



            Copyright 2019 Regulatory News Service, all rights reserved